XENE Stock Forecast 2025-2026
Distance to XENE Price Targets
XENE Price Momentum
10 Quality Stocks Worth Considering Now
Researching Xenon (XENE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on XENE and similar high-potential opportunities.
Latest XENE Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, XENE has a bullish consensus with a median price target of $60.00 (ranging from $42.00 to $65.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $34.95, the median forecast implies a 71.7% upside. This outlook is supported by 17 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 86.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XENE Analyst Ratings
XENE Price Target Range
Latest XENE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XENE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $53.00 |
| Feb 11, 2025 | Deutsche Bank | David Hoang | Buy | Initiates | $67.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $53.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $53.00 |
| Nov 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $60.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Outperform | Reinstates | $50.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $53.00 |
| Sep 3, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $55.00 |
| Aug 12, 2024 | Needham | Serge Belanger | Buy | Maintains | $60.00 |
| Aug 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $65.00 |
| Aug 9, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $49.00 |
| Jun 18, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $55.00 |
| May 10, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $50.00 |
| May 10, 2024 | Citigroup | David Hoang | Buy | Maintains | $60.00 |
| May 10, 2024 | Needham | Serge Belanger | Buy | Maintains | $62.00 |
| Apr 12, 2024 | Needham | Serge Belanger | Buy | Reiterates | $62.00 |
| Apr 10, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $65.00 |
| Mar 1, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $51.00 |
| Mar 1, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $55.00 |
| Mar 1, 2024 | Needham | Serge Belanger | Buy | Maintains | $62.00 |
Xenon Pharmaceuticals Inc. (XENE) Competitors
The following stocks are similar to Xenon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xenon Pharmaceuticals Inc. (XENE) Financial Data
Xenon Pharmaceuticals Inc. has a market capitalization of $2.79B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -27.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Xenon Pharmaceuticals Inc. (XENE) Business Model
About Xenon Pharmaceuticals Inc.
Develops therapeutics for neurological disorders.
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on advancing its research and development pipeline for targeted treatment candidates. The company generates revenue primarily through partnerships and collaborations with other organizations, leveraging its proprietary technologies and expertise in ion channel genetics to develop innovative therapies, particularly in niche areas like epilepsy and rare neurological conditions.
Based in Canada, Xenon collaborates with global scientific and medical communities to translate its research into clinical success, aiming to address unmet medical needs in the biotechnology sector and improve the lives of patients with neurological diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
316
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Country
Canada
IPO Year
2014
Website
www.xenon-pharma.comXenon Pharmaceuticals Inc. (XENE) Latest News & Analysis
Xenon Pharmaceuticals (Nasdaq: XENE) will present at the Stifel 2025 Virtual CNS Forum on March 18-19, 2025, focusing on its neuroscience biopharmaceutical developments.
Xenon Pharmaceuticals' presentation at a key industry forum could attract investor interest, potentially impacting its stock price and signaling advancements in its drug development pipeline.
Xenon Pharmaceuticals Inc. will host its Q4 2024 earnings conference call on February 27, 2025, at 4:30 PM ET, featuring key executives and analysts from major financial firms.
The announcement of Xenon Pharmaceuticals' upcoming earnings call indicates potential updates on financial performance and strategic direction, which can influence stock valuation and investor sentiment.
Azetukalner's Phase 3 topline data for its FOS epilepsy program is expected in H2 2025, which will support NDA filing and potential commercial launch.
Positive Phase 3 data for azetukalner could lead to FDA approval and market entry, potentially boosting the company's stock value and revenue prospects significantly.
XENE reported a narrower Q4 2024 loss than anticipated. Its development programs for azetukalner in epilepsy and MDD are advancing positively.
XENE's narrower loss indicates improved financial health, while progress in drug development could lead to future revenue, positively impacting stock performance and investor confidence.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) will present at the 45th Annual TD Cowen Healthcare Conference in Boston from March 3-5, 2025.
Xenon Pharmaceuticals' presentation at a prominent healthcare conference may signal potential developments or partnerships, influencing investor sentiment and stock performance.
Xenon Pharmaceuticals (Nasdaq: XENE) will release its Q4 2024 financial results after U.S. markets close on February 27, 2025.
Xenon Pharmaceuticals' upcoming Q4 2024 financial results may impact its stock price and investor sentiment, reflecting the company's performance and future outlook in the biopharmaceutical sector.
Frequently Asked Questions About XENE Stock
What is Xenon Pharmaceuticals Inc.'s (XENE) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Xenon Pharmaceuticals Inc. (XENE) has a median price target of $60.00. The highest price target is $65.00 and the lowest is $42.00.
Is XENE stock a good investment in 2025?
According to current analyst ratings, XENE has 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XENE stock?
Wall Street analysts predict XENE stock could reach $60.00 in the next 12 months. This represents a 71.7% increase from the current price of $34.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xenon Pharmaceuticals Inc.'s business model?
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on advancing its research and development pipeline for targeted treatment candidates. The company generates revenue primarily through partnerships and collaborations with other organizations, leveraging its proprietary technologies and expertise in ion channel genetics to develop innovative therapies, particularly in niche areas like epilepsy and rare neurological conditions.
What is the highest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The highest price target for XENE is $65.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 86.0% increase from the current price of $34.95.
What is the lowest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The lowest price target for XENE is $42.00 from at , which represents a 20.2% increase from the current price of $34.95.
What is the overall XENE consensus from analysts for Xenon Pharmaceuticals Inc.?
The overall analyst consensus for XENE is bullish. Out of 19 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are XENE stock price projections?
Stock price projections, including those for Xenon Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
